Yubin Kang | Scholars@Duke

Yubin Kang
Professor of Medicine

Current Appointments & Affiliations

Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2021
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2013

Contact Information

Box 3961 Med Ctr, Durham, NC 27710
Hematologic Malignancies, Box 3961, Durham, NC 27710
yubin.kang@duke.edu (919) 668-1000

Background
Education, Training, & Certifications
- Fellow, Hematology, Oncology, Cellular Therpay, Duke University School of Medicine 2007 - 2010
- M.D., Shanghai Second Medical University (China) 1991
Previous Appointments & Affiliations
- Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2019 - 2020
- Associate Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2015 - 2019
- Instructor Temporary in the Department of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2014 - 2015
Research
Selected Grants
- Targeting convergent oncogenic signaling during AR inhibition to overcome metastasis and immune evasion in prostate cancer awarded by National Institutes of Health 2019 - 2025
- Investigating the Role of a Novel Dendritic Cell Subset within Sentinel Lymph Node Tissues in Immune Evasion and Melanomagenesis awarded by Department of Defense 2021 - 2024
- Epigenomic Reprogramming in Patient Derived Models of Colorectal Cancer awarded by National Institutes of Health 2018 - 2023
- Targeting the p38/Snail/PD-L1 axis in hormone-therapy resistance and metastasis awarded by Department of Defense 2018 - 2022
- A PHASE 2, MULTICENTER, MULTI-COHORT, OPEN-LABEL STUDY OF POMALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE OR POMALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE AND DARATUMUMAB IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA awarded by Celgene Corporation 2017 - 2022
- Effects of PPAR agonists on response to immunomodulatory agents in patients with multiple myeloma awarded by National Institutes of Health 2019 - 2021
- Phase I study of Pomolidomide, Bortezomib, and Dexamethasone (PVD) as First-Line treatment of AL Amyloidosis or Light Chain Deposition Disease awarded by Karmanos Cancer Center 2014 - 2021
- Targeting sphingosine kinase 2 for the treatment of multiple myeloma awarded by National Institutes of Health 2015 - 2021
- Transfusion Medicine and Hematology awarded by National Institutes of Health 1975 - 2021
- Clinical characteristics, JAK2 status, and macrophage infiltration in multiple myeloma patients with marrow fibrosis awarded by Incyte Corporation 2017 - 2020
- Clinical Trial of ABC294640 in Patients with Refractory Multiple Myeloma awarded by Apogee Biotechnology Corporation 2015 - 2019
- Ph III study to evaluate the safety of ALN-TTR02 in TTR-Medicated Polyneuropathy awarded by Alnylam Pharmaceuticals 2014 - 2018
- Thioredoxin for radioprotection awarded by Columbia University 2016 - 2018
- Develop and Support of the RedCap database, bio-statistic analysis, and med writing for Dr Kang NIH SBIR award Clin Trial awarded by RedHill Biopharma Ltd. 2016 - 2018
- Plerixafor for allogeneic hematopoietic stem cell transplantation awarded by National Institutes of Health 2014 - 2016
External Relationships
- Blue Bird
- IONIS Pharmaceuticals
- PSI CRO Deutschland GmbH
- Sanofi Genzyme
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Bal, Susan, Ehsan Malek, Ankit Kansagra, Saad Z. Usmani, Ravi Vij, Kelly N. Godby, Robert F. Cornell, et al. “Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies.” Leukemia, November 20, 2021. https://doi.org/10.1038/s41375-021-01471-3.
    Full Text
  - Costa, Luciano J., Yi Lin, R Frank Cornell, Thomas Martin, Saurabh Chhabra, Saad Z. Usmani, Sundar Jagannath, et al. “Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.” Clinical Lymphoma, Myeloma & Leukemia, October 30, 2021. https://doi.org/10.1016/j.clml.2021.10.013.
    Full Text
  - Choi, Taewoong, and Yubin Kang. “Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma.” Pharmacol Ther, September 25, 2021, 108007. https://doi.org/10.1016/j.pharmthera.2021.108007.
    Full Text Link to Item
  - Wu, Jian, Emily Chu, and Yubin Kang. “PIM Kinases in Multiple Myeloma.” Cancers (Basel) 13, no. 17 (August 26, 2021). https://doi.org/10.3390/cancers13174304.
    Full Text Link to Item
  - Maung, Ko K., Benny J. Chen, Ian Barak, Zhiguo Li, David A. Rizzieri, Cristina Gasparetto, Keith M. Sullivan, et al. “Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation.” Bone Marrow Transplant 56, no. 1 (January 2021): 137–43. https://doi.org/10.1038/s41409-020-0991-5.
    Full Text Link to Item
  - Cornell, Robert, Parameswaran Hari, Shijie Tang, Noa Biran, Natalie Callander, Ajai Chari, Saurabh Chhabra, et al. “Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.” Am J Hematol 96, no. 1 (January 2021): E5–8. https://doi.org/10.1002/ajh.26010.
    Full Text Link to Item
  - Kumar, Shaji K., Natalie S. Callander, Kehinde Adekola, Larry Anderson, Muhamed Baljevic, Erica Campagnaro, Jorge J. Castillo, et al. “Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 18, no. 12 (December 2, 2020): 1685–1717. https://doi.org/10.6004/jnccn.2020.0057.
    Full Text Link to Item
  - Dupuis, Megan M., Barry Paul, Gavin Loitsch, Parker Mathews, Daniel Feinberg, Ian Barak, Zhiguo Li, Sascha A. Tuchman, and Yubin Kang. “Gamma Gap: A Point-of-Care Test That Correlates With Disease Burden and Treatment Response in Multiple Myeloma.” Jco Oncol Pract 16, no. 8 (August 2020): e751–57. https://doi.org/10.1200/JOP.19.00517.
    Full Text Link to Item
  - Paul, Barry, Yue Zhao, Gavin Loitsch, Daniel Feinberg, Parker Mathews, Ian Barak, Megan Dupuis, et al. “The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.” Cancer Med 9, no. 16 (August 2020): 5869–80. https://doi.org/10.1002/cam4.3265.
    Full Text Link to Item
  - Theivanthiran, Balamayoora, Kathy S. Evans, Nicholas C. DeVito, Michael Plebanek, Michael Sturdivant, Luke P. Wachsmuth, April Ks Salama, et al. “A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.” J Clin Invest 130, no. 5 (May 1, 2020): 2570–86. https://doi.org/10.1172/JCI133055.
    Full Text Link to Item
  - Huang, Qiang, Malkiel A. Cohen, Fernando C. Alsina, Garth Devlin, Aliesha Garrett, Jennifer McKey, Patrick Havlik, et al. “Intravital imaging of mouse embryos.” Science 368, no. 6487 (April 10, 2020): 181–86. https://doi.org/10.1126/science.aba0210.
    Full Text Open Access Copy Link to Item
  - Fan, Shengjun, Trevor Price, Wei Huang, Michelle Plue, Jonathan Warren, Pasupathi Sundaramoorthy, Barry Paul, et al. “PINK1-Dependent Mitophagy Regulates the Migration and Homing of Multiple Myeloma Cells via the MOB1B-Mediated Hippo-YAP/TAZ Pathway.” Adv Sci (Weinh) 7, no. 5 (March 2020): 1900860. https://doi.org/10.1002/advs.201900860.
    Full Text Link to Item
  - Feinberg, Daniel, Barry Paul, and Yubin Kang. “The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.” Cell Immunol 345 (November 2019): 103964. https://doi.org/10.1016/j.cellimm.2019.103964.
    Full Text Link to Item
  - Kumar, Shaji K., Natalie S. Callander, Jens Hillengass, Michaela Liedtke, Muhamed Baljevic, Erica Campagnaro, Jorge J. Castillo, et al. “NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020.” J Natl Compr Canc Netw 17, no. 10 (October 1, 2019): 1154–65. https://doi.org/10.6004/jnccn.2019.0049.
    Full Text Link to Item
  - Gandhi, Ujjawal H., Robert F. Cornell, Arjun Lakshman, Zhubin J. Gahvari, Elizabeth McGehee, Megan H. Jagosky, Ridhi Gupta, et al. “Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.” Leukemia 33, no. 9 (September 2019): 2266–75. https://doi.org/10.1038/s41375-019-0435-7.
    Full Text Link to Item
  - Rizzieri, Dustin, Barry Paul, and Yubin Kang. “Metabolic alterations and the potential for targeting metabolic pathways in the treatment of multiple myeloma.” J Cancer Metastasis Treat 5 (2019). https://doi.org/10.20517/2394-4722.2019.05.
    Full Text Link to Item
  - Zheng, Jing, Yonggang Sha, Logan Roof, Oded Foreman, John Lazarchick, Jagadish Kummetha Venkta, Cleopatra Kozlowski, et al. “Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.” Cancer Lett 440–441 (January 2019): 1–10. https://doi.org/10.1016/j.canlet.2018.10.003.
    Full Text Link to Item
  - Paul, Barry, Shuqi Kang, Zhihong Zheng, and Yubin Kang. “The challenges of checkpoint inhibition in the treatment of multiple myeloma.” Cell Immunol 334 (December 2018): 87–98. https://doi.org/10.1016/j.cellimm.2018.10.003.
    Full Text Link to Item
  - Sivaraj, Dharshan, Michael M. Green, Yubin Kang, Gwynn D. Long, David A. Rizzieri, Zhiguo Li, Anderson H. Garrett, Jackie L. McIntyre, Nelson J. Chao, and Cristina Gasparetto. “Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma.” Blood Cancer J 8, no. 8 (July 31, 2018): 71. https://doi.org/10.1038/s41408-018-0104-5.
    Full Text Link to Item
  - Sundaramoorthy, Pasupathi, Cristina Gasparetto, and Yubin Kang. “The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation.” Cancer Med, May 15, 2018. https://doi.org/10.1002/cam4.1543.
    Full Text Link to Item
  - Zheng, Zhihong, Shengjun Fan, Jing Zheng, Wei Huang, Cristina Gasparetto, Nelson J. Chao, Jianda Hu, and Yubin Kang. “Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma.” Journal of Hematology & Oncology 11, no. 1 (February 27, 2018): 29. https://doi.org/10.1186/s13045-018-0575-7.
    Full Text
  - Kumar, Shaji K., Natalie S. Callander, Melissa Alsina, Djordje Atanackovic, J Sybil Biermann, Jorge Castillo, Jason C. Chandler, et al. “NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.” J Natl Compr Canc Netw 16, no. 1 (January 2018): 11–20. https://doi.org/10.6004/jnccn.2018.0002.
    Full Text Link to Item
  - Sivaraj, D., W. Bacon, G. D. Long, D. A. Rizzieri, M. E. Horwitz, K. M. Sullivan, Y. Kang, Z. Li, N. J. Chao, and C. Gasparetto. “High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.” Bone Marrow Transplant 53, no. 1 (January 2018): 34–38. https://doi.org/10.1038/bmt.2017.208.
    Full Text Link to Item
  - Sundaramoorthy, Pasupathi, Qinhong Wang, Zhihong Zheng, Yiqun Jiao, Benny J. Chen, Phuong L. Doan, Nelson J. Chao, and Yubin Kang. “Thioredoxin mitigates radiation-induced hematopoietic stem cell injury in mice.” Stem Cell Research & Therapy 8, no. 1 (November 15, 2017): 263. https://doi.org/10.1186/s13287-017-0711-2.
    Full Text
  - Tuchman, Sascha A., Joseph O. Moore, Carlos D. DeCastro, Zhiguo Li, Emily Sellars, Yubin Kang, Gwynn Long, and Cristina G. Gasparetto. “Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone ("VCD-Lite") in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma.” J Geriatr Oncol 8, no. 3 (May 2017): 165–69. https://doi.org/10.1016/j.jgo.2017.02.004.
    Full Text Link to Item
  - Sivaraj, Dharshan, Michael M. Green, Zhiguo Li, Anthony D. Sung, Stefanie Sarantopoulos, Yubin Kang, Gwynn D. Long, et al. “Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.” Biol Blood Marrow Transplant 23, no. 2 (February 2017): 262–68. https://doi.org/10.1016/j.bbmt.2016.11.010.
    Full Text Link to Item
  - Green, Michael M. B., Nelson Chao, Saurabh Chhabra, Kelly Corbet, Cristina Gasparetto, Ari Horwitz, Zhiguo Li, et al. “Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery.” J Hematol Oncol 9, no. 1 (August 17, 2016): 71. https://doi.org/10.1186/s13045-016-0301-2.
    Full Text Open Access Copy Link to Item
  - An, Ningfei, Bo Cen, Houjian Cai, Jin H. Song, Andrew Kraft, and Yubin Kang. “Pim1 kinase regulates c-Kit gene translation.” Exp Hematol Oncol 5 (2016): 31. https://doi.org/10.1186/s40164-016-0060-3.
    Full Text Link to Item
  - Schade, Henning, Saurabh Chhabra, Yubin Kang, Robert K. Stuart, Kathy H. Edwards, Cindy Kramer, Coleen Butcher, et al. “Similar dynamics of intraapheresis autologous CD34+ recruitment and collection efficiency in patients undergoing mobilization with or without plerixafor.” Transfusion 54, no. 12 (December 2014): 3131–37. https://doi.org/10.1111/trf.12761.
    Full Text
  - Venkata, Jagadish Kummetha, Ningfei An, Robert Stuart, Luciano J. Costa, Houjian Cai, Woodrow Coker, Jin H. Song, et al. “Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.” Blood 124, no. 12 (September 18, 2014): 1915–25. https://doi.org/10.1182/blood-2014-03-559385.
    Full Text Link to Item
  - Venkata, Jagadish Kummetha, Ningfei An, Robert Stuart, Luciano J. Costa, Houjian Cai, Woodrow Coker, Jin H. Song, et al. “Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.” Blood 124, no. 12 (September 18, 2014): 1915–25. https://doi.org/10.1182/blood-2014-03559385.
    Full Text Link to Item
  - Costa, Luciano J., Elizabeth J. Nista, Francis K. Buadi, Martha Q. Lacy, Angela Dispenzieri, Cindy P. Kramer, Kathy H. Edwards, et al. “Prediction of Poor Mobilization of Autologous CD34+ Cells with Growth Factor in Multiple Myeloma Patients: Implications for Risk-Stratification.” Biology of Blood and Marrow Transplantation 20, no. 2 (February 2014): 222–28. https://doi.org/10.1016/j.bbmt.2013.11.003.
    Full Text
  - Roof, Logan, Woodrow J. Coker, John Lazarchick, and Yubin Kang. “Senile transthyretin cardiac amyloidosis in patients with plasma cell dyscrasias: importance of cardiac biopsy for making the correct diagnosis.” Aperito J Cell Mol Biol 1, no. 1 (2014).
    Link to Item
  - An, Ningfei, and Yubin Kang. “Thioredoxin and hematologic malignancies.” Adv Cancer Res 122 (2014): 245–79. https://doi.org/10.1016/B978-0-12-420117-0.00007-4.
    Full Text Link to Item
  - An, Ningfei, Andrew S. Kraft, and Yubin Kang. “Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice.” Journal of Hematology & Oncology 6, no. 1 (December 2013). https://doi.org/10.1186/1756-8722-6-12.
    Full Text
  - Coker, Woodrow J., Ashley Jeter, Henning Schade, and Yubin Kang. “Plasma cell disorders in HIV-infected patients: epidemiology and molecular mechanisms.” Biomarker Research 1, no. 1 (December 2013). https://doi.org/10.1186/2050-7771-1-8.
    Full Text
  - Kellner, Joshua, Bei Liu, Yubin Kang, and Zihai Li. “Fact or fiction - identifying the elusive multiple myeloma stem cell.” Journal of Hematology & Oncology 6, no. 1 (December 2013). https://doi.org/10.1186/1756-8722-6-91.
    Full Text
  - An, Ningfei, Michael G. Janech, Alison M. Bland, John Lazarchick, John M. Arthur, and Yubin Kang. “Proteomic analysis of murine bone marrow niche microenvironment identifies thioredoxin as a novel agent for radioprotection and for enhancing donor cell reconstitution.” Experimental Hematology 41, no. 11 (November 2013): 944–56. https://doi.org/10.1016/j.exphem.2013.08.004.
    Full Text
  - An, Ningfei, Ying-Wei Lin, Sandeep Mahajan, Joshua N. Kellner, Yong Wang, Zihai Li, Andrew S. Kraft, and Yubin Kang. “Pim1 Serine/Threonine Kinase Regulates the Number and Functions of Murine Hematopoietic Stem Cells.” Stem Cells 31, no. 6 (June 1, 2013): 1202–12. https://doi.org/10.1002/stem.1369.
    Full Text
  - Zhou, Dunhua, Divino Deoliveira, Yubin Kang, Seung S. Choi, Zhiguo Li, Nelson J. Chao, and Benny J. Chen. “Insulin-like growth factor 1 mitigates hematopoietic toxicity after lethal total body irradiation.” Int J Radiat Oncol Biol Phys 85, no. 4 (March 15, 2013): 1141–48. https://doi.org/10.1016/j.ijrobp.2012.08.014.
    Full Text Link to Item
  - Butler, Charles, Daynna J. Wolff, Yubin Kang, Robert K. Stuart, and Luciano J. Costa. “Association of age with fluorescencein situhybridization abnormalities in multiple myeloma reveals higher rate ofIGHtranslocations among older patients.” Leukemia & Lymphoma 53, no. 12 (December 2012): 2444–48. https://doi.org/10.3109/10428194.2012.691483.
    Full Text
  - Jeter, Ashley, and Yubin Kang. “Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy.” Experimental Hematology & Oncology 1, no. 1 (December 2012). https://doi.org/10.1186/2162-3619-1-20.
    Full Text
  - Costa, L. J., J. Abbas, K. R. Hogan, C. Kramer, K. McDonald, C. D. Butcher, A. Littleton, K. Shoptaw, Y. Kang, and R. K. Stuart. “Growth factor plus preemptive (‘just-in-time’) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure.” Bone Marrow Transplantation 47, no. 11 (November 2012): 1403–8. https://doi.org/10.1038/bmt.2012.60.
    Full Text
  - Costa, Luciano J., Cindy Kramer, Kathy R. Hogan, Coleen D. Butcher, Amanda L. Littleton, Katie B. Shoptaw, Yubin Kang, and Robert K. Stuart. “Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.” Transfusion 52, no. 11 (November 2012): 2375–81. https://doi.org/10.1111/j.1537-2995.2012.03579.x.
    Full Text
  - Costa, Luciano J., Jonathan Abbas, Karen L. Ortiz-Cruz, Yubin Kang, and Robert K. Stuart. “Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange.” European Journal of Haematology 89, no. 5 (November 2012): 432–34. https://doi.org/10.1111/ejh.12008.
    Full Text
  - Kang, Yubin, Benny J. Chen, Divino Deoliveira, Jeffrey Mito, and Nelson J. Chao. “Selective enhancement of donor hematopoietic cell engraftment by the CXCR4 antagonist AMD3100 in a mouse transplantation model.” Plos One 5, no. 6 (June 28, 2010): e11316. https://doi.org/10.1371/journal.pone.0011316.
    Full Text Open Access Copy Link to Item
  - Kang, Yubin, Nelson J. Chao, and Franco Aversa. “Unmanipulated or CD34 selected haplotype mismatched transplants.” Curr Opin Hematol 15, no. 6 (November 2008): 561–67. https://doi.org/10.1097/MOH.0b013e32831366eb.
    Full Text Link to Item
  - Kang, Yubin, Christopher J. Moressi, Todd E. Scheetz, Litao Xie, Diane Thi Tran, Thomas L. Casavant, Prashanth Ak, Craig J. Benham, Beverly L. Davidson, and Paul B. McCray. “Integration Site Choice of a Feline Immunodeficiency Virus Vector.” Journal of Virology 80, no. 17 (September 2006): 8820–23. https://doi.org/10.1128/jvi.00719-06.
    Full Text
  - Kang, Yubin, Litao Xie, Diane Thi Tran, Colleen S. Stein, Melissa Hickey, Beverly L. Davidson, and Paul B. McCray. “Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer.” Blood 106, no. 5 (September 1, 2005): 1552–58. https://doi.org/10.1182/blood-2004-11-4358.
    Full Text
  - Song, L., J. Wang, R. Wang, M. Yu, Y. Sun, G. Han, Y. Li, et al. “Retroviral delivery of GAD-IgG fusion construct induces tolerance and modulates diabetes: a role for CD4+ regulatory T cells and TGF-β?” Gene Therapy 11, no. 20 (October 2004): 1487–96. https://doi.org/10.1038/sj.gt.3302327.
    Full Text
  - Starner, Timothy D., Carrie K. Barker, Hong Peng Jia, Yubin Kang, and Paul B. McCray. “CCL20 Is an Inducible Product of Human Airway Epithelia with Innate Immune Properties.” American Journal of Respiratory Cell and Molecular Biology 29, no. 5 (November 2003): 627–33. https://doi.org/10.1165/rcmb.2002-0272oc.
    Full Text
  - Kang, Yubin, Colleen S. Stein, Jason A. Heth, Patrick L. Sinn, Andrea K. Penisten, Patrick D. Staber, Kenneth L. Ratliff, et al. “In Vivo Gene Transfer Using a Nonprimate Lentiviral Vector Pseudotyped with Ross River Virus Glycoproteins.” Journal of Virology 76, no. 18 (September 15, 2002): 9378–88. https://doi.org/10.1128/jvi.76.18.9378-9388.2002.
    Full Text
  - Melo, M. E. F., J. Qian, M. El-Amine, N. Soukhareva, Y. Kang, and D. W. Scott. “Gene transfer of immunoglobulin-fusion proteins prevents and treats autoimmune diseases.” J. Immunol 168, no. 9 (2002): 4788–95.
  - Stein, C. S., Y. Kang, S. L. Sauter, K. Townsend, P. Staber, T. A. Derken, I. Martins, J. Qian, B. L. Davidson, and P. B. McCray. “In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using non-primate lentiviral vectors.” Molecular Therapy 3 (2001): 850–56.
  - Agarwal, Rajeev K., Yubin Kang, Elias Zambidis, David W. Scott, Chi-Chao Chan, and Rachel R. Caspi. “Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis.” Journal of Clinical Investigation 106, no. 2 (July 15, 2000): 245–52. https://doi.org/10.1172/jci9168.
    Full Text
  - El-Amine, M., M. E. F. Melo, Y. Kang, J. Qian, and D. W. Scott. “Mechanisms of tolerance induction by an Ig-peptide molecule expressed and secreted by B cells.” Journal of Immunology (Baltimore, Md. : 1950) 165 (2000): 5631–36.
  - Kang, Y., M. Melo, E. Deng, R. Tisch, M. El-Amine, and D. W. Scott. “Induction of hyporesponsiveness to intact foreign protein via retroviral-mediated gene expression: The IgG scaffold is important for induction and maintenance of immune hyporesponsiveness.” Proceedings of the National Academy of Sciences 96, no. 15 (July 20, 1999): 8609–14. https://doi.org/10.1073/pnas.96.15.8609.
    Full Text
  - Kang, Y., M. E. F. Melo, and D. W. Scott. “An Ongoing Immune Response to HIV Envelope gp120 in Human CD4 Transgenic Mice Contributes to T Cell Decline upon Intravenous Administration of gp120.” European Journal of Immunology 28 (1998): 2253–64.
  - Thornalley, P. J., L. G. Edwards, Y. Kang, C. Wyatt, N. Davies, M. J. Ladan, and J. Double. “Antitumour activity of S-p-bromobenzylglutathione cyclopentyl diester in vitro and in vivo. Inhibition of glyoxalase I and induction of apoptosis.” Biochem Pharmacol 51, no. 10 (May 17, 1996): 1365–72. https://doi.org/10.1016/0006-2952(96)00059-7.
    Full Text Link to Item
  - Kang, Yubin, Linda G. Edwards, and Paul J. Thornalley. “Effect of methylglyoxal on human leukaemia 60 cell growth: Modification of DNA, G1 growth arrest and induction of apoptosis.” Leukemia Research 20, no. 5 (May 1996): 397–405. https://doi.org/10.1016/0145-2126(95)00162-x.
    Full Text
  - Thornalley, P. J., M. Ladan, S. Ridgeway, and Y. Kang. “Anti-tumor Activity of S-(p-bromobenzyl)glutathione Diesters in vitro: a Structure-Activity Study.” Journal of Medicinal Chemistry 39, no. 17 (1996): 3409–11.
  - Huang, L. A., P. L. Meng, Y. Kang, Q. S. Cheng, and B. T. Liu. “Clinical Observation and Prevention of Coagulation Abnormality in 7 Cases of Patients with Acute Radiation Sickness.” Edited by B. T. Liu and G. Y. Ye, 1994, 348–56.
  - Huang, L. A., Q. S. Cheng, Y. Kang, and Y. H. Li. “Cytomegalovirus Infection in Bone Marrow Transplant Patients with Acute Radiation Sickness.” Edited by B. T. Liu and G. Y. Ye, 1994, 315–19.
  - Kang, Y., C. N. Gu, P. L. Meng, L. X. Cao, and L. A. Huang. “Monitoring of Blood Cyclosporine A Concentration and Clinical Observation in Patients with HLA-semimatched Bone Marrow Transplantation.” Edited by B. T. Liu and G. Y. Ye, 1994, 402–9.
  - Kang, Y., S. W. Zing, P. L. Meng, L. X. Cao, and L. A. Huang. “Capillary Leakage Syndrome Associated with Acute Radiation Disease.” Edited by B. T. Liu and G. Y. Ye, 1994, 311–14.
  - Kang, Y., R. Q. Yu, and X. T. Kong. “Tumor Cell Surface Markers and Differentiation on Multiple Myeloma.” Chinese Journal of Hematology 7 (1992): 384–87.
  - Kang, Y., and R. Q. Yu. “Hypertension Associated with Cyclosporine A Treatment in Bone Marrow Transplantation.” Foreign Medicine (Blood Transfusion & Hematology) 5 (1991): 288–91.
  - Kang, Y., and R. Q. Yu. “Therapeutic Progress in Multiple Myeloma.” Foreign Medicine (Blood Transfusion & Hematology) 3 (1990): 140–43.
  - An, Ningfei, and Yubin Kang. “Using Quantitative Real-time PCR to Determine Donor Cell Engraftment in a Competitive Murine Bone Marrow Transplantation Model.” Journal of Visualized Experiments, no. 73 (n.d.). https://doi.org/10.3791/50193.
    Full Text
- Book Sections
  - Kang, Y., and N. J. Chao. “Strategies to enhance hematopoietic stem cell engraftment following transplantation.” In Novel Developments in Stem Cell Mobilization Focus on CXCR4, 439–56. Springer Science & Business Media, 2012.
  - Kang, Y., and N. Chao. “Immune reconstitution.” In Hematopoietic Stem Cell Transplantation A Handbook for Clinicians, edited by J. R. Wingard, D. Gastineau, H. Leather, E. C. Snyder, and Z. M. Szczepiokowski, 181–96. Bethesda, MD: AABB Press, 2010.
  - Kang, Y., and J. He. “Interleukin-4.” In A Handbook of Human Cytokines, edited by J. He and D. X. Wang, 97–112. China: Tong Zi University Press, 1996.
  - Kang, Y., and Y. B. Cheng. “A Handbook of Human Cytokines.” In Interleukin-3, edited by J. He and D. X. Wang, 79–96. China: Tong Zi University Press, 1996.
- Digital Publications
  - An, N., and Y. Kang. “In vivo BrdU Incorporation Assay for Murine Hematopioetic Stem Cells.” Bio-Protocol, 2013.
    Link to Item
- Conference Papers
  - Theivanthiran, Balamayooran, Kathy Evans, Nicholas DeVito, Michael Plebanek, Michael Sturdivant, Alisha Holtzhausen, Luke Wachsmuth, et al. “A tumor PD-L1-NLRP3 inflammasome signaling axis drives adaptive resistance to anti-PD-1 immunotherapy.” In Journal for Immunotherapy of Cancer, Vol. 7. BMC, 2019.
    Link to Item
  - Cornell, Robert, Hari Parameswaran, Shijie Tang, Alyssa Barnstead, Noa Biran, Natalie Callander, Ajai Chari, et al. “Real world vs. clinical trial outcomes of triple class refractory penta-exposed multiple myeloma (MM).” In Clinical Lymphoma Myeloma and Leukemia, 19:e115–16. Elsevier BV, 2019. https://doi.org/10.1016/j.clml.2019.09.191.
    Full Text
  - Paul, Barry, Gavin Loitsch, Daniel Feinberg, Ian Barak, Zhiguo Li, Endi Wang, Yue Zhao, Megan Dupuis, and Yubin Kang. “The presence of bone marrow fibrosis is associated with poorer prognosis in newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.” In Journal of Clinical Oncology, Vol. 37. AMER SOC CLINICAL ONCOLOGY, 2019.
    Link to Item
  - Maung, Ko Ko, Benny J. Chen, David A. Rizzieri, Cristina Gasparetto, Keith Sullivan, Gwynn D. Long, Ashley Morris Engemann, et al. “Phase I, Dose Escalation Study of Naive T-Cell Depleted Donor Lymphocyte Infusion Following Allogeneic Stem Cell Transplantation.” In Biology of Blood and Marrow Transplantation, Vol. 25, 2019.
    Link to Item
  - Kang, Y., S. Fan, P. Sundaramoorthy, C. Gasparetto, G. Long, A. Garrett, E. Sellars, et al. “Sphingosine kinase 2 (SK2) targeting in the treatment of multiple myeloma: preclinical and phase I studies of opaganib, an SK 2 inhibitor, in multiple myeloma.” In European Journal of Cancer, 103:E124–E124. ELSEVIER SCI LTD, 2018.
    Link to Item
  - Paul, Barry, Daniel Feinberg, Pasupathi Sundaramoorthy, J Brice Weinberg, and Yubin Kang. “Relationship of acquired resistance of myeloma cells to bortezomib with Lyn and Src induced inhibition of PP2A and effect of treatment with the tyrosine kinase inhibitor dasatinib.” In Journal of Clinical Oncology, 36:8047–8047. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.8047.
    Full Text
  - Sung, Anthony D., Carlos M. de Castro, Thomas W. LeBlanc, Gwynn D. Long, Donna B. Adams, Danielle M. Brander, Sandeep Dave, et al. “Clinical Outcomes of Microtransplantation for Older Adults with Acute Myeloid Leukemia.” In Blood, Vol. 130. AMER SOC HEMATOLOGY, 2017.
    Link to Item
  - Sivaraj, Dharshan, Michael M. Green, Yubin Kang, David Rizzieri, Louis F. Diehl, Anne W. Beaven, Zhiguo Li, et al. “Phase I/II dose expansion of a trial investigating bendamustine and pomalidomide with dexamethasone (BPd) in patients with relapsed/refractory multiple myeloma.” In Journal of Clinical Oncology, 35:8008–8008. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.8008.
    Full Text
  - Gasparetto, Cristina, Michael Green, Anandgopal Srinivasan, Yubin Kang, David A. Rizzieri, Carlos Decastro, Louis F. Diehl, et al. “A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.” In Blood, 126:1857–1857. American Society of Hematology, 2015. https://doi.org/10.1182/blood.v126.23.1857.1857.
    Full Text
  - Green, Michael M. B., Mitchell E. Horwitz, Yubin Kang, Nelson J. Chao, Gwynn D. Long, David Rizzieri, Cristina Gasparetto, et al. “Administration of Plerixafor (a CXCR4 antagonist) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Enhances Platelet Recovery in a Phase I/II Trial.” In Biology of Blood and Marrow Transplantation, 21:S31–32. Elsevier BV, 2015. https://doi.org/10.1016/j.bbmt.2014.11.024.
    Full Text
  - Zhou, Dunhua, Divino Deoliveira, Yubin Kang, Seung S. Choi, Nelson J. Chao, and Benny J. Chen. “Insulin-Like Growth Factor 1 Mitigates Hematopoietic Toxicity After Lethal Total Body Irradiation.” In Biology of Blood and Marrow Transplantation, 19:S198–S198. Elsevier BV, 2013. https://doi.org/10.1016/j.bbmt.2012.11.214.
    Full Text
  - An, Ningfei, Yeong-Bin Im, Yingwei Lin, Cristina Gasparetto, Luciano J. Costa, Robert K. Stuart, Charles Smith, Andrew Kraft, and Yubin Kang. “Characterization of Pim Protein Kinases and Evaluation of Small Molecule Inhibitors in Multiple Myeloma.” In Blood, 118:1254–55. AMER SOC HEMATOLOGY, 2011.
    Link to Item
  - Kang, Y., A. DeOliveira, L. E. Peel, D. -. F. Chen, and N. Chao. “A Prospective Study Of Donor Immuknow® As A Biomarker For Acute GvHD In Hematopoietic Cell Transplantation Recipients.” In Biology of Blood and Marrow Transplantation, 16:S311–S311. Elsevier BV, 2010. https://doi.org/10.1016/j.bbmt.2009.12.463.
    Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Previous Appointments & Affiliations

Selected Grants

External Relationships

Selected Publications

Academic Articles

Book Sections

Digital Publications

Conference Papers